NMD Pharma will ‘accelerate’ rare disease drug ignaseclant despite endpoint miss
But phase II data of the small molecule inhibitor for…
But phase II data of the small molecule inhibitor for Charcot-Marie-Tooth disease Types 1 and 2 did show it meeting secondary endpoints for functional improvements.





